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A phase I study of the bispecific antibody MDX-H210 in combination with granulocyte colony-stimulating factor (G-CSF) was
performed in stage IV breast carcinoma patients, overexpressing HER-2/neu. MDX-H210, constructed by crosslinking antigen binding
fragments (F(ab0) fragments) of monoclonal antibody (mAb) H22 to Fc gamma receptor I (FcgRI), and mAb 520C9 to HER-2/neu,
respectively, mediates the lysis of tumour cells in vitro, and in human FcgRI transgenic mouse models. The proto-oncogene HER-2/neu
is overexpressed in approximately 30% of breast cancer patients, and represents a promising target for antibody-based
immunotherapy. Fc gamma receptor I (CD64) is an effective trigger molecule, which is expressed on monocytes/macrophages,
immature dendritic cells, and G-CSF-primed polymorphonuclear cells (PMN). Patients received G-CSF (Filgrastim) for 8 consecutive
days, and cohorts of three patients were treated on day 4 with escalating, single doses of MDX-H210. A total of 30 patients were
included, and treatment was generally well tolerated, without reaching dose-limiting toxicity. Side effects consisted mainly of fever and
short periods of chills, which were timely related to elevated plasma levels of interleukin 6 and tumour necrosis factor alpha. In the
last two cohorts, MDX-H210 plasma levels exceeded 1mgml
 1, and on circulating myeloid cells 450% saturation of FcgRI was
found until day 4. These effector cells were highly effective in antibody-dependent cell-mediated cytotoxicity. Immunohistochemical
analyses of tumour biopsies in individual patients documented infiltration of monocytes and PMN after MDX-H210 infusion.
Although the clinical course of the disease was not altered by the single dose of MDX-H210, a favourable toxicity profile – even at
high doses – and remarkable biological effects were seen when combined with G-CSF. Therefore, the combination of G-CSF and
MDX-H210 should be evaluated in further immunotherapeutical strategies.
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Breast cancer represents a major public health problem in the
Western world. In case of localised disease, cure rates have
improved, but in women with metastatic disease results are still
disappointing (Hortobagyi, 1998). Therefore, novel therapeutical
approaches are under investigation. In the last decade, along with
new chemotherapeutical drugs, developments in the field of
immunology and genetic engineering have raised new perspec-
tives. For example, Trastuzumab (Herceptin
s), a humanised IgG1
monoclonal antibody (mAb) with specificity for HER-2/neu, has
been approved for patients with metastatic breast cancer. As a
single agent, the overall response rate was 15% in heavily
pretreated patients with HER-2/neu overexpressing metastatic
breast cancer (Cobleigh et al, 1999; Baselga, 2001).
The HER-2/neu gene encodes a 185–190000 molecular weight
transmembrane protein with tyrosine kinase activity. Overex-
pressed HER-2/neu has transforming activity, and in a variety of
human carcinomas, gene amplification and protein overexpression
have been demonstrated. This includes approximately 30% of
breast cancer, in which it has been correlated with the develop-
ment of metastases and is associated with poor prognosis (Slamon
et al, 1987). In addition, HER-2/neu has limited expression on
normal tissue, suggesting that it may constitute a valuable target
for antibody therapy (Pegram and Slamon, 2000). Although many
mechanisms have been proposed to account for the antitumour
activities of therapeutical antibodies – including blockade of
signalling pathways, activation of apoptosis, and antibody-
dependent cell-mediated cytotoxicity (ADCC) – the relevance of
Received 10 February 2003; revised 18 August 2003; accepted 9
September 2003
*Correspondence: Dr R Repp;
E-mail: Roland.Repp@med3.imed.uni-erlangen.de
10These authors contributed equally to this study
wDr Wolfgang Becker Sadly passed away recently.
British Journal of Cancer (2003) 89, 2234–2243
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
C
l
i
n
i
c
a
lthese mechanisms in humans is still unclear (Houghton and
Scheinberg, 2000). In mice, the significance of Fc receptor-bearing
effector cells is clearly demonstrated by the reduced efficacy of
Trastuzumab to arrest tumour growth in animals deficient in
activating Fc receptors (Clynes et al, 2000).
Three different classes of leucocyte receptors for IgG (FcgR)
have been distinguished in humans (van de Winkel and Capel,
1993; Ravetch and Bolland, 2001). Fc gamma receptor I (FcgRI)
(CD64) is constitutively expressed on myeloid precursors in the
bone marrow, monocytes/macrophages, immature dendritic cells,
and can be induced on polymorphonuclear cell (PMN) by
interferon gamma (IFN-g) or granulocyte colony-stimulating
factor (G-CSF) (Perussia et al, 1983; Repp et al, 1991). FcgRI is
unique among FcgR because of its high affinity for IgG, the limited
cell expression solely on cytotoxic effector cells, and because of its
inherent capacity to trigger cytotoxic effector cells. Furthermore,
FcgRI contains a distinct cytoplasmatic domain, which targets
antigens to MHC class II-containing vesicles, and thereby,
enhances antigen presentation (van Vugt et al, 1999).
Bispecific antibodies (BsAbs) can effectively link target cells to
cytotoxic trigger molecules on immune effector cells, and may
overcome some of the limitations of conventional mAb (Segal et al,
1999). For example, high concentrations of serum immunoglobu-
lins compete in vivo for binding to FcgRI on immune effector cells.
Hereby, the ability of therapeutical antibodies to trigger FcgRI
could be impaired. To overcome this problem, the BsAb MDX-
H210 was constructed by chemical crosslinking of F(ab0) fragments
from humanised mAb 22 (H22), directed to FcgRI, and mAb
520C9, to the proto-oncogene product HER-2/neu, respectively.
Monoclonal antibody H22 binds to a site distinct from the ligand-
binding site, yet effectively triggers FcgRI-mediated cellular
responses (such as phagocytosis, respiratory burst, and ADCC)
in the presence of high concentrations of human serum IgG (Guyre
et al, 1989; Valerius et al, 1993). To influence the effector cell
system specifically, G-CSF was added to the treatment schedule to
increase the absolute numbers of PMN, to induce the expression of
FcgRI (Repp et al, 1991), and to enhance their functional capacity
(Valerius et al, 1993). Preclinical studies demonstrated the binding
of MDX-H210 to FcgRI on G-CSF-primed PMN and to HER-2/neu
on SK-BR-3 breast carcinoma cells to be comparable to the
respective parental mAb. More importantly, in vitro MDX-H210
was highly cytotoxic to HER-2/neu overexpressing cell lines, when
FcgRI-positive PMN from G-CSF-treated patients served as effector
cells (Stockmeyer et al, 1997; Stockmeyer et al, 2001). In addition,
studies in an FcgRI-transgenic animal model reported synergism of
FcgRI-directed BsAb and G-CSF, resulting in antitumour activity
and in ‘memory’ induction (Honeychurch et al, 2000).
To analyse whether these preclinical observations may translate
into the clinical situation, MDX-H210 in combination with G-CSF
was tested in a phase I study. The primary objectives of this trial
were to define the maximum tolerated dose (MTD), and to identify
the optimal biologically active dose of MDX-H210. The secondary
objective was to assess the clinical responses.
PATIENTS AND METHODS
Patients
Patients, aged 18–70 years, with stage IV breast cancer were
eligible if their primary tumour or metastases were overexpressing
HER-2/neu. The expression of HER-2/neu was determined on
paraffin-embedded tissues using standard immunohistochemical
methods (Venter et al, 1987). Inclusion in the trial demanded a
2þ or 3þ membrane staining (van de Vijver, 2001). Patients
needed to be progressive after at least two standard chemotherapy
or hormonal regimens, or one hormonal and one chemotherapy
regimen. Sufficient blood cell counts, normal hepatic, and renal
function, as well as an Eastern Cooperative Oncology Group
performance status of o3, and a life expectancy of more than 3
months were required. The protocol was approved by the local
Ethics Committee, and written informed consent before treatment
was obligatory.
Study design
Bispecific antibody MDX-H210 was given as a single, 2-h
intravenous (i.v.) infusion, in combination with a fixed subcuta-
neous (s.c.) dose of 5mgkg
 1 Filgrastim for 8 days in the
afternoon, with a minimum of 4h after the end of MDX-H210
on day 0 (Table 1). Filgrastim was started 3 days before the
administration of MDX-H210 to ensure maximal expression of
FcgRI on neutrophils (Repp et al, 1991). The dose of MDX-H210
was escalated in cohorts of three patients, and not in an individual
patient. For the first cohort of patients, Filgrastim was skipped if
the absolute neutrophil count (ANC) was higher than 20000ml
 1
to prevent toxicity. As no toxicity was observed, the upper limit for
ANC was raised to 50000ml
 1 from the second cohort onwards. In
the first two cohorts, the same dose of MDX-H210 (0.35mgm
 2)
was given. Patients treated in the third to tenth cohort received
escalating doses of MDX-H210 from 1 up to 200mgm
 2 (1, 3.5, 7,
10, 15, 30, 100, and 200mgm
 2). Dose-limiting toxicity (DLT) was
defined as the dose where three or more patients in a cohort of six
patients experienced grade III or IV toxicity, and the MTD as the
dose level below which DLT occurred. Reassessment for tumour
response was performed after 30 days. If patients had an objective
response or stable disease, a second treatment on compassionate
use basis was possible for patients enrolled during the last period
according to an amendment. The overall goals of this phase I trial
were to determine toxicity, MTD, pharmacokinetics, and pharma-
codynamics of MDX-H210, to describe the biological effects of
MDX-210 in combination with Filgrastim, and to elucidate the
effects of Filgrastim on immune effector cells.
Production of MDX-H210
Bispecific antibody MDX-H210 (FcgRI HER-2/neu) was pro-
duced by chemically crosslinking F(ab0) fragments of mAb 22
against FcgRI (CD64) with mAb 520C9 against HER-2/neu, as
described by Glennie et al (1987). Briefly, F(ab0g)2 fragments were
produced by limited proteolysis with pepsin, and were then
reduced to provide F(ab0g) with free hinge region SH groups. The
SH groups on one of the F(ab0g)-SH partners were then fully
alkylated with excess o-phenylendimaleimide (o-PDM) to provide
free maleimide groups. Finally, the two o-PDM and F(ab0)-SH
preparations F(ab0) were combined at a ratio of 1:1 to generate
heterochimeric constructs. After purification by size exclusion
chromatography, the binding activity of the individual
components was verified by flow cytometry, using HER-2/
neu-expressing SK-BR-3 cells, FcgRI-expressing human mono-
cytes, and U937 cells as targets. The bispecific nature of the
Table 1 Treatment schedule
Day  3  2  101234
Filgrastim s.c. (5mgkg
 1) x x x xxxxx
MDX-H210 i.v. (dose escalation
a)x
aMDX-H210 is given as a single 2h infusion with escalating doses from 0.35 up to 200mgm
 2.
Immunotherapy with BsAb MDX-H210 with Filgrastim
R Repp et al
2235
British Journal of Cancer (2003) 89(12), 2234–2243 & 2003 Cancer Research UK
C
l
i
n
i
c
a
lconstruct was confirmed by a solid-phase immunoassay. MDX-
H210 was produced according to GMP guidelines by Medarex
(Medarex Inc., Annandale, NJ, USA), and shipped as a clear
colourless liquid in sterile phosphate-buffered saline for i.v.
infusion.
Assessment of adverse reactions
Patients were hospitalised on day  1 and MDX-H210 was
administered as a 2-h i.v. infusion on day 0 (Table 1). The vital
signs were frequently monitored during and for 24h after the
administration of the BsAb. Afterwards, patients were checked on
an outpatient basis. Laboratory tests were performed daily starting
on day  3 with additional time points 2, 4, and 8h after the start
of MDX-H210 infusion. Toxicity was graded according to the NCI
Common Toxicity Criteria. For dose escalation, transient leuco-
penia, neutropenia without signs of infection, or fever with mild
hypotension were not graded as toxicity, because these symptoms
were known to be correlated to MDX-H210 infusion, and to
recover spontaneously (Valone et al, 1995).
Pharmacokinetics
Blood samples were obtained before and 2, 4, 8, 24, 48, 72,
and 96h after BsAb infusion. Plasma was immediately
separated and stored at  701C until analysis. Microtitre plates,
coated with goat antimurine IgG, were incubated with serial
dilutions of the patient’s plasma, or with MDX-H210 diluted in
normal human plasma (Nabi Inc., Boca Raton, FL, USA). The
captured BsAb was detected by an alkaline phosphatase-conju-
gated antimurine IgG. Pharmacokinetic analysis was performed
using PKPD Tools for Excel Version 1.02 (Charles Minto, Stanford,
CA, USA) with a constant i.v. infusion open noncompartmental
model.
Cytokines, tumour markers, and plasma HER-2/neu levels
Plasma – separated and stored as described above – was analysed
for levels of interleukin (IL)-1a, IL-1b, IL-2, IL-6, IL-10, IFN-g,
tumour necrosis factor alpha (TNF-a), G-CSF, soluble IL-2
receptor (sIL-2R), CEA, CA125, and CA15.3 by enzyme-linked
immunosorbent assay using kits according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA). Plasma HER-
2/neu was measured by enzyme immunosorbent assay using a
commercial kit (Chiron Diagnostics, Alameda, CA, USA).
Radioimaging with Technetium-99m (
99mTc) MDX-H210
Antibody labelling was performed according to a published kit-
formulated NHS-BAT (NHS¼N-hydroxysuccinimide and
BAT¼bis(aminoethanethid)type) ester conjugation (Eisenhut
et al, 1996). Briefly, NHS ester of the BAT ligand, 6-(40(400-
carboxyphenoxy)butyl)-2,10-dimercapto-2.10-dimethyl-4,8-di-
zaun-decane was conjugated with MDX-H210 at ambient tempera-
ture, and pH ranging from pH 7.0 to pH 8.5. Unreacted or
hydrolysed NHS-BAT ester was separated by one or two
ultracentrifugation steps (for 15min each). The conjugation yield
was 70–80% independent of pH. Complexation of the BsAb
conjugate with
99mTc was accomplished using Sn(II)-tartrate as a
reducing agent. Within 5min, labelling yield 495% was achieved
using 1mg BAT-MDX-H210 comprising about three BAT ligands
per antibody, and up to 1.5GBq
99mTc-pertechnetate. Localisation
of MDX-H210 in normal and tumour tissues was investigated in a
subset of patients who voluntarily participated, using planar
whole-body scans, and single photon emission tomography
(SPECT) images of the regions of interest.
Granulocyte scintigraphy with Indium-111-oxine
(
111In)-labelled PMN
Autologous granulocytes were isolated using a Percoll/plasma
gradient, and labelled with
111In-oxine as described (Becker et al,
1986). Labelled granulocytes were reinfused either 30min before,
or 72h after application of MDX-H210. Dynamic imaging was
performed with a gamma camera linked to a computer system
during 2h after injection of labelled cells to trace the route of PMN.
Human antibispecific antibody (HABA) response
Microtitre plates coated with MDX-H210 were incubated with
dilutions of plasma samples. Anti-MDX-H210 antibodies were
detected with an alkaline-phosphatase-conjugated goat anti-hu-
man IgG Fc-specific probe. The dilution of plasma required to
reach the background level (A405¼0.1) was determined for
samples before infusion, and on days 7, 14, and 30 postinfusion.
Human antibispecific antibody levels were expressed as x-fold
increase over the baseline preinfusion value.
Assessment of biological effects
Isolation of effector cells A measure of 10–20ml of peripheral
blood was drawn from patients or healthy donors (HDs) after
informed consent. The total leucocyte counts in whole blood were
determined on an EPICSt Profile flow cytometer (Coulter,
Hialeah, FL, USA), and PMN counts in whole blood were
calculated from the total leucocyte counts and differentials of
Wright-stained blood smears. Isolated PMN were obtained by a
method slightly modified from that described in Repp et al (1991).
Briefly, citrate anticoagulated blood was layered over a discontin-
uous Percoll (Seromed, Berlin, Germany) gradient consisting of 70
and 62% for HD, and of 68 and 59% of Percoll for Filgrastim
recipients, respectively. After centrifugation, PMN were collected
at the interphase between the two Percoll layers, and mononuclear
cells from the Percoll/plasma interphase. The remaining erythro-
cytes were removed by hypotonic lysis. The purity of PMN was
determined by cytospin preparations and exceeded 95%, with few
contaminating eosinophils and o1% mononuclear cells. The
viability of cells tested by Trypan blue exclusion was always
exceeding 95%.
Immunofluorescence Antibodies 32.2 (FcgRI, CD64; mIgG1)
(Guyre et al, 1989), IV.3 (FcgRII, CD32; mIgG2b) (Looney et al,
1986), 3G8 (FcgRIII, CD16; mIgG1) (Fleit et al, 1982), and 520C9
(HER-2/neu; mIgG1) (Ring et al, 1989) were obtained from
Medarex Inc. (Annandale, NJ, USA). Whole blood (100ml) was
incubated with different lineage-specific FITC- or RPE-conjugated
antibodies (CD3, CD4, CD8, CD20, CD11b, CD56, CD67) for 30min
at 41C. Afterwards, samples were subjected to FACS
s Lysing
solution to lyse red blood cells and fix white cells. Cells were then
washed three times in phosphate-buffered saline supplemented
with 1% bovine serum albumin, and analysed on an EPICSt
Profile flow cytometer (Coulter). For each cell population, the
relative fluorescence intensity (RFI) was calculated as the ratio of
mean linear fluorescence intensity of relevant to irrelevant,
isotype-controlled antibodies.
ADCC assay Antibody-dependent cell-mediated cytotoxicity was
performed as described (Valerius et al, 1993). Briefly, human SK-
BR-3 breast carcinoma cells were used as the target. This cell line
was obtained from the American Type Culture Collection
(Manassas, VA, USA), and kept in an RF10
þ medium consisting
of RPMI 1640 medium (Gibco BRL, Paisley, Scotland) supple-
mented with 10% heat-inactivated foetal calf serum, 100Uml
 1
penicillin, 100Uml
 1 streptomycin, and 4mML -glutamine (all
Gibco BRL). The target cells were labelled with 200mCi
51Cr for 2h.
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lAfter extensive washing with RF10
þ, cells were adjusted to
10
5ml
 1. Isolated PMN, effector-to-target ratio 80:1 (E:T, 80:1),
or 50ml of whole blood as effector source, sensitising antibodies
and RF10
þ were added into round-bottom microtitre plates. By
adding the target cell suspension, giving a final volume of 200ml,
the assays were started. After 3h at 371C, assays were stopped by
centrifugation, and
51Cr release from triplicates was measured in
counts per minute (c.p.m.). The percentage of cellular cytotoxity
was calculated using the formula:
%specificlysis ¼
experimentalc:p:m:   basalc:p:m:
maximalc:p:m:   basalc:p:m:
 100
with maximal
51Cr release determined by adding perchloric acid
(3% final concentration) to target cells, and basal release measured
in the absence of sensitising antibodies and effector cells. Only
very low levels of antibody-mediated noncellular cytotoxicity
(without effector cells) were observed under these assay conditions
(o5% specific lysis). Low levels of antibody-independent killing
were seen in whole-blood assays (Figure 6).
Oxidative burst and phagocytosis The activity of neutrophil
respiratory burst was measured by a method modified from Smith
and Weidemann (1993). In short, 100ml of whole blood was
incubated for 15min with 1mlo f2 0,70-dichlorofluorescein diacetate
(200mM solution in ethanol; Molecular Probes, Eugene, OR, USA).
After stimulation for 15min with 1mgml
 1 PMA (Sigma,
Deisenhofen, Germany), red cell lysis and fixation of white cells
was obtained by Q-prep (Coulter). Fluorescence of single cells was
measured on an EPICSt Profile flow cytometer (Coulter), and the
results were analysed comparing mean fluorescence intensity.
For measurement of phagocytosis, fluorescent polystyrene beads
(1.0mm in diameter; Fluoresbrite, Polysciences Inc., Warrington,
PA, USA) were opsonised with human albumin or polyclonal
human IgG, respectively, according to the manufacturer’s instruc-
tions for coupling proteins to carboxylated polystyrene micro-
particles (Carbodiimide method, Polysciences Inc., Warrington,
PA, USA). A measure of 2ml of 2.5% carboxylated microparticles
were added to 100ml whole blood, and incubated for 30min at
371C. Red cell lysis and fixation of white cells was obtained by Q-
prep, and the fluorescence of single cells was measured on an
EPICSt Profile flow cytometer (Coulter). Polymorphonuclear cell
populations were gated according to forward light scatter and
perpendicular light scatter. Data were expressed as the percentage
of PMN-containing FITC-labelled beads and the mean number of
beads per PMN (calculated from the fluorescence intensity of PMN
with a single particle ingested).
Statistical analysis
Group data are reported as mean7standard deviation (s.d.). The
differences between groups were analysed by unpaired (or, when
appropriate, paired) Student’s t-tests. Levels of significance are
indicated. Data presented correspond to the whole patient
population, or is indicated when different.
RESULTS
Patient characteristics
In all, 30 women with metastatic breast cancer were treated in this
trial. Three patients were treated in each of 10 cohorts received
escalating doses of MDX-H210 from 0.35 up to 200mgm
 2. The
first and second cohorts were treated with 0.35mgm
 2 with an
upper limit of the ANC of 20000ml
 1 in the first and 50000ml
 1
from the second cohort onwards. Their ages ranged from 40 to 69
years, with a median age of 50 years. The median time from
diagnosis was 70.2 months. Patients were heavily pretreated, but
had not received previous antibody therapy (Table 2).
Pharmacokinetics
Plasma levels of MDX-H210 were measured up to 4 days after BsAb
infusion (Figure 1). The mean t1/2 values ranged from 4.76h in the
3.5mgm
 2 cohort to 17.41h in the 200mgm
 2. Cmax values were
correlated with the applied dose, and varied from 0.24mgl
 1 at the
1mgm
 2 level to 155.7mgl
 1 at the 100mgm
 2 dose level
(Table 3). At the 200mgm
 2 dose level, infusion of MDX-H210
was temporarily stopped in two patients because of chills and
vomiting during the infusion period and restarted after about 1h.
Owing to the prolonged infusion time, Cmax was lower compared to
the 100mgm
 2 dose level and was reached after 4h (Table 3). Both
granulocytes and monocytes were opsonised with MDX-H210 at
the end of the infusion, and continued to be ‘armed’ with MDX-
H210 up to 4 days after the infusion of 200mgm
 2 (Figure 2), with
a comparable expression of FcgRI (CD64) on days 0 and 3
(Figure 4).
Toxicity
In the current study, the combination of MDX-H210 with
Filgrastim was well tolerated with minimal to moderate toxicity
Table 2 Patient characteristics
Patient demographics
Total number 30
Age (years) 50 (40–69)
Median time since diagnosis (months) 70.2 (7.1–181.6)
Metastatic sites 2 (1–5)
Prior therapy
Chemotherapy 2 (0–6)
Radiotherapy 1 (0–7)
Hormonal treatment 2 (0–4)
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Figure 1 Plasma levels of MDX-H210. Plasma levels of MDX-H210 in
the different patient cohorts were determined 2, 4, 8, 24, 48, 72, and 96h
after BsAb infusion. The related pharmacokinetic parameters are described
in Table 3. Data presented relate to all participating patients treated with
X10mgm
 2.
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 2 (Table 4). No grade IV toxicity
occurred. Nonhaematological toxicities consisted mainly of short
periods of chills, low-grade fever, nausea, and vomiting all
occurring towards the end of the MDX-H210 infusion. Most side
effects resolved spontaneously within 8h, or could easily be treated
with either acetaminophen or antiemetics. Several patients
complained about pain at metastatic sides, possibly related to
local inflammatory reactions in tumour tissue induced by the
BsAb, or to therapy-related cytokine release. A one- to two-fold
increase of alkaline phosphatase and gGT was noted, which was
maximal after 3–4 days, and resolved spontaneously after 1 week.
Haematological changes were mainly related to the treatment
medication. After the start of Filgrastim an asymptomatic
granulocytosis emerged. At 2h after infusion of MDX-H210,
granulocytes and monocytes decreased dramatically. However,
these values returned to preinfusion levels within approximately
12h. Lymphocytes, which do not express FcgRI, also demonstrated
a significant drop after infusion of MDX-H210. Red blood cell
counts and platelet numbers did not significantly change
(Figure 3).
Receptor expression
At 72h after the start of Filgrastim, all blood PMN expressed FcgRI
(CD64), declining slowly after G-CSF cessation (Figure 4). A small
increase of FcgRI expression was seen on monocytes. Within 2h
after the start of MDX-H210, a transient decrease of FcgRI
expression was seen on monocytes and PMN, suggesting a more
rapid decline of FcgRI-positive cells. Interestingly, FcgRII
(CD32) expression on monocytes and PMN was also increased
during Filgrastim application, whereas FcgRIII (CD16) expression
of PMN significantly decreased. The expression of CD67 on PMN,
and of CD11b on PMN and monocytes increased after the
administration of MDX-H210, probably due to concomitant
cytokine release.
Functional assays
ADCC, phagocytosis, and oxidative burst In vitro cytotoxicity
assays against SK-BR-3 breast cancer cells with isolated PMN
demonstrated significantly enhanced cytotoxicity in the presence
of MDX-H210 during, but not before or 1 week after the start of
Filgrastim application (Figure 5). A small decrease in ADCC
activity of PMN on day 1 probably reflected the reduced FcgRI
expression on the remaining circulating PMN.
Spontaneous cytotoxicity of whole blood, without the addition
of MDX-H210 in vitro could be demonstrated on day 1 in cohorts
treated with doses above 10mgm
 2, lasting up to day 4 with doses
above 100mgm
 2 (Figure 6). This spontaneous cytotoxicity
documented adequate circulating MDX-H210 levels to induce
ADCC, and was in agreement with the measurement of cell-bound
MDX-H210 (Figure 2).
Phagocytosis of IgG-coated beads by PMN was increased during
Filgrastim application, with a further increase 24h after MDX-
H210 infusion. In contrast, phagocytosis of albumin-coated beads
did not change (Figure 7).
Baseline oxidative burst, unstimulated and stimulated with
PMA, was comparable to HDs (60.5722.1 vs 59.8729.0 and
151.5725.8 vs 149.6725.7, respectively). A slight increase of PMA-
stimulated oxidative burst was seen during Filgrastim
(158.3723.2; P¼0.07), which increased to significant values 24h
after the application of MDX-H210 (163.7721.6; P¼0.01),
returning to baseline on day 4.
Cytokines, HABA Cytokine plasma concentrations were mea-
sured at baseline, and at several time points during the study.
Elevated levels of IL-6 and TNF-a were consistently found during
the first hour after MDX-H210 infusion (Figure 8), and related to
flu-like symptoms. Peak levels of TNF-a and IL-6 did not correlate
to the dose of BsAb applied. Whereas peak levels of TNF-a were
reached after 2h, IL-6 levels were maximal after 4h. The anti-
inflammatory cytokine IL-10 also increased, with a maximum after
2h. Granulocyte colony-stimulating factor plasma levels increased
during the application of Filgrastim, with a small, additional
increase after MDX-H210 infusion. Soluble IL-2 receptor increased
after the start of Filgrastim, and reached its maximum after MDX-
H210. Serum levels of IFN-g, IL-1a, IL-1b, IL-2, and IL-12 were not
altered during the study period. Human antibispecific antibody
Table 3 Plasma pharmacokinetics
Dose level
a (mgm
 2) t1/2 (h) Cmax
b (lgml
 1) Tmax (h) AUC
c (lgh
 1ml
 1) b
d Vd
e (lkg
 1)C l
f (mlmin
 1kg
 1)
1 — 0.24 2 — — — —
3.5 4.76 1.28 2.7 9.33 0.180 0.070 0.747
7 5.19 5.95 2 41.90 0.137 0.036 0.300
10 10.54 5.82 3.3 65.22 0.078 0.063 0.269
15 6.09 6.72 2.7 70.72 0.117 0.052 0.417
30 9.00 29.34 2.7 381.06 0.078 0.027 0.134
100 9.53 155.27 2.7 1937.77 0.073 0.020 0.091
200 17.41 109.00 4 2523.08 0.041 0.049 0.147
aPharmacokinetic results could not be determined accurately for dose level 0.35mgm
 2 because low plasma concentrations of MDX-H210 resulted in very few measurements.
bMaximal concentration.
cArea under the curve.
dElimination rate constant b.
eVolume of distribution.
fPlasma clearance.
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Figure 2 Cell-bound MDX-H210. The total number of FcgRI expressed
by circulating cells was determined after incubation with a saturating dose
of MDX-H210. Patients were divided into three groups according to
treatment with low (0.35–7mgm
 2), medium (10–30mgm
 2), and high
(100–200mgm
 2) doses of MDX-H210. Cell-bound murine IgG without
or with this preincubation was determined by incubation with FITC-labelled
goat anti-mouse mAb. Significant amount of bound MDX-H210 was found
on monocytes and PMN on day 1 in the low-dose group and days 1–4 in
the medium- and high-dose group (Po0.05).
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lwas detected in 19 patients on day 30, in seven of them X16 times
above baseline.
Scintigraphy The number of circulating PMN rapidly decreased
after the tart of MDX-H210 infusion. In order to evaluate whether
G-CSF-activated PMN could cause additional toxicity, for example,
by trapping of PMN in the lung, dynamic granulocyte imaging was
performed with
111In-labelled autologous granulocytes infused
30min prior to MDX-210 infusion. A normal distribution of
granulocytes with no abnormal accumulation at any particular site
was found (patient #3). In two patients, either
111In-labelled
(patient #12) or
99mTc-HMPAO-labelled autologous granulocytes
(patient #23) were infused 72h after the administration of MDX-
H210. Imaging of the liver, spleen, and bone marrow was normal.
However, sites of bone metastasis were spared (patient #12), and
soft-tissue metastases did not image well. In three patients (patient
#6, #11, and #28), 200mgo f
99mTc-labelled MDX-H210 was injected
simultaneously with unlabelled antibody, resulting in imaging of
the liver, spleen, and bone marrow, but without imaging tumour
Table 4 Maximum nonhaematological toxicity
Cohort (mgm
 2)/toxicity (grade)
Dose level (number of patients) 0.35 (n¼6) 1 (n¼3) 3.5 (n¼3) 7 (n¼3) 10 (n¼3) 15 (n¼3) 30 (n¼3) 100 (n¼3) 200 (n¼3)
Toxicity grade 1/2 3 1/2 3 1/2 3 1/2 3 1/2 3 1/2 3 1/2 3 1/2 3 1/2 3
Nausea 3 2 2 3 3 2 3 2 1 1
Vomiting 1 2 2 3 3 1 3 3 1 1
Fever 3 3 3 3 3 3 3 3 2
Chills 3 3 2 1 1 1 2 1 1
Hepatic 5 3 3 1 3 3 2 1 2 1
Respiratory 1 1 1 1 1 1 1 1
Tachycardia 1 1 2 1 2 2
Hypotension 1 1 1 1 3 2
Tumour pain 2 2 1 2 1 1 3 1
Redness of skin 1 1 1
Diarrhoea 11
Emotional 1 1
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Figure 3 Effects of MDX-H210 on circulating white blood cells numbers.
In all patients, ANC increased during Filgrastim application. A significant
drop of ANC, monocytes, and lymphocytes was observed after infusion of
MDX-H210 with a minimum 2–4h after start of BsAb infusion. Data
presented relate to all participating patients.
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Figure 4 Receptor expression of PMN and monocytes during treatment
with MDX-H210/Filgrastim. Receptor expression was determined by flow
cytometry and expressed as RFI. Changes from days  3 to 0 are attributed
to the effect of Filgrastim; further changes were noted after start of the 2h
during infusion of MDX-H210 on day 0. Data presented relate to all
participating patients. **Significant changes (Po0.05) were seen for all
tested antigens between days  3 and 0 and for all, except CD11b on
monocytes between day 0 and the end of MDX-H210 infusion. No
significant differences were seen between days  3 and 30.
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Figure 5 ADCC of isolated PMN via MDX-H210. Isolated PMN from
HD were compared with PMN from patients in their capacity to mediate
cytotoxicity against SK-BR-3 breast cancer cells in the presence of
0.4mgml
 1 MDX-H210 at an E:T ratio of 80:1. Lysis of SK-BR-3 by
PMN from patients on days 0, 1, and 4 is significantly higher compared to
day  3 (before start of Filgrastim) as well as compared to healthy controls
(Po0.005, indicated by *). Data presented (mean7s.d.) relate to a subset
of 26 patients and 26 HDs.
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lsites. In patient #28, however, asymptomatic brain metastases were
detected by SPECT. Since these lesions were also seen with
99mTc-
DTPA SPECT without antibody, a nonspecific imaging due to an
altered blood–brain barrier has to be considered. In all three
patients, activity was detected in the gut, suggesting excretion of
labelled MDX-H210 via the bile duct.
Response
No objective responses were seen in this single dose study in
advanced patients. A total of 11 patients had stable, and 19 patients
progressive disease at the end of the study period. Three patients
with metastatic skin lesions developed an erythema between days 1
and 4 after the administration of MDX-H210. In one of them, a
skin biopsy was performed before and 3 days after MDX-H210
application. Immunohistochemical analyses revealed local infiltra-
tion of mononuclear cells and PMN at the tumour site (Figure 9). A
control biopsy before the study showed no effector cell infiltration.
Patient #29 (200mgm
 2) demonstrated a reduction of CA 15.3–
40.2% (341 vs 137Eml
 1) and CEA to 37.8% (64.9 vs 24.1UGl
 1)
on day 30, increasing later again. Soluble HER-2/neu levels
increased 4h after infusion of MDX-H210 in average by
25.2723.2Uml
 1 (P¼0.045) in patients treated with 0.35mgm
 2,
whereas an early drop was seen in most of the patients treated with
higher doses (mean decrease of 32.9736.7Uml
 1; Po0.001). The
mean decrease of all patients was maximal on day 7 (mean
0
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Figure 6 Spontaneous cytotoxicity. For whole-blood ADCC, citrate
anticoagulated, freshly drawn blood was added to
51Cr-labelled SK-BR-3
cells without the addition of antibody. Patients were divided into three
groups according to treatment with low (0.35–7mgm
 2), medium (10–
30mgm
 2), and high (100–200mgm
 2) doses of MDX-H210. Significant
enhanced lysis was seen in patients of the high-dose group (day 1 vs day 0,
Po0.05, indicated by *). The medium- and high-dose group showed
enhanced lysis compared to the low-dose group on day 1 (#: Po0.05; ##:
Po0.01). Patients treated with high doses of MDX-H210 (X100mgm
 2)
showed a trend toward enhanced lysis of SK-BR-3 even 4 days after MDX-
H210 infusion, although not statistically significant.
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Figure 7 Phagocytosis of latex beads by PMN during treatment with
MDX-H210. Phagocytosis of 1.0mM fluorescent polystyrene beads, coated
with human albumin and polyvalent human IgG, respectively, was measured
by flow cytometry. Mean beads per neutrophil from a patient and an HD
measured simultaneously were calculated as described in Material and
Methods. The relation of beads per PMN of patient to HD is expressed.
Phagocytosis of IgG-coated beads is significantly higher on days 0 and 1
(Po0.05, indicated by *) compared to baseline (day  3).
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Figure 8 Cytokine plasma levels. Mean plasma levels of all patients are
shown. Plasma levels of IL-6 and TNF-a increase after the infusion of MDX-
H210 with a maximum 2h after the start of infusion. Anti-inflammatory
cytokine IL-10 is released with a similar time kinetic. G-CSF levels begin to
rise after the start of Filgrastim therapy, with a further significant increase
after MDX-H210. Plasma levels of sIL-2R and G-CSF were significantly
different between days  3 and 0 (Po0.001). Significant differences
(Po0.05) of plasma levels before (day 0) and after infusion of MDX-H2120
were seen for TNF-a (8h and 1 day after start of MDX-H210), IL-6 (2h
and 1 day after start of MDX-H210), and sIL-2R (from 2h up to 3 days
after start of MDX-H210). No significant release of IL-1a, IL-1b, IL-2, IFN-g,
and IL-12 was seen.
HER-2/neu Macrophages PMN
Figure 9 Immunohistochemical staining of a skin biopsy. A skin biopsy
taken 3 days after the administration of MDX-H210 (patient #21) was
stained for macrophages and PMN. Macrophages (arrow) were stained
with a CD68 antibody, and PMN (arrow) with chloroacetate esterase. A
skin biopsy from the same patient taken before the start of treatment
showed no relevant infiltration with macrophages and PMN.
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ldecrease of 34.8779.0Uml
 1; P¼0.034), while on day 30 this was
less impressive (a mean decrease of 26.2776.8Uml
 1; P¼0.083)
(Figure 10).
DISCUSSION
Based on our preclinical data (Stockmeyer et al, 1997), the
combination of MDX-H210 and G-CSF was analysed in a phase I
study, performed in 30 heavily pretreated breast carcinoma
patients overexpressing HER-2/neu. This phase I trial was
designed to determine the tolerability, safety, and MTD of BsAb
MDX-H210 (anti-FcgRI anti-HER-2/neu) in combination with
Filgrastim. Aside from clinical toxicity, we focused on the
biological activity, and pharmacokinetics of the combination.
Treatment was generally well tolerated, with a successful dose
escalation of MDX-H210 up to 200mgm
 2 without reaching MTD.
Nonhaematologic toxicity appeared within the first 2–4h, was
mainly infusion related, and consisted of transient fever, chills,
nausea and vomiting, and hypotension. Tumour necrosis factor
alpha and IL-6 levels increased timely related to the side effects
with a maximum after 2 and 4h, respectively. Interestingly,
toxicity appeared not to be dose related, in line with comparable
peak levels of IL-6 and TNF-a in all cohorts above 0.35mgm
 2.
Despite high peak levels of IL-6 and TNF-a, exceeding 300 pgml
 1,
side effects were only moderate, which might be due to the absence
of IL-1 and IFN-g (Waage et al, 1989), and to antagonistic effects of
an early release of anti-inflammatory cytokines such as IL-10.
Furthermore, G-CSF might contribute to an enhanced anti-
inflammatory cytokine response (Hartung et al, 1995). Concomi-
tant administration of MDX-H210 and G-CSF seems to be safe in
our study as well as in a multidose trial with MDX-H210 (Pullarkat
et al, 1999). Interestingly, the side effects in our study were similar
to other MDX-H210 studies, with other cytokines such as IFN-g or
GM-CSF (Posey et al, 1999; Lewis et al, 2001). On the other hand,
the addition of G-CSF led to unacceptable toxicity in combination
with an anti-FcgRI anti-EGFR BsAb (MDX-447) (Pfister et al,
1999).
As MDX-H210 is designed to trigger phagocytic cells, the
transient drop in ANC and monocytes was not surprising.
Additional haematological changes were a more than 10-fold
increase of circulating PMN, due to Filgrastim, and all PMN
expressed FcgRI. Pulmonary toxicity, resulting from entrapment of
activated FcgRI-positive PMN in the lungs, was considered to be a
potential risk from G-CSF administration. Therefore, in some
patients imaging with
111In-labelled granulocytes was performed.
However, we did not observe increased clinical pulmonary toxicity
nor did we observe abnormal accumulation of PMN in the lung.
Three patients were retreated because of stable disease after 30
days. Strikingly less side effects were noted in these patients. This
desensitisation phenomenon was also reported in other clinical
trials with BsAb or mAb (Maloney et al, 1997; Dillman, 1999; Posey
et al, 1999; Pullarkat et al, 1999).
In patients with advanced cancer, the cytotoxic capabilities
of effector cells are often impaired (Brittenden et al, 1996).
In contrast, granulocyte function was not diminished in
our patients with regard to phagocytosis and oxidative burst,
and was even further enhanced during G-CSF treatment.
Isolated PMN were highly cytotoxic in vitro in the presence of
MDX-H210, concomitant with the induction of FcgRI expression
during G-CSF application. Maximum lysis was achieved at a
concentration of 0.4mgml
 1, with reduced efficacy at higher doses,
probably resulting from inhibition by monomeric binding of
MDX-H210 to effector and tumour cells (Stockmeyer et al, 1997).
Plasma concentrations of MDX-H210 exceeding 1mgkg
 1
were already found in the 3.5mgm
 2 cohort; with increasing
peak levels and AUC up to 200mgm
 2 with a serum half-life
of 4–10h, increasing to 17h at doses of 200mgm
 2. Granulocytes
and monocytes of patients treated at the 200mgm
 2 cohort
documented complete saturation of FcgRI by BsAb for
up to 4 days. These ‘armed’ effector cells are functionally active
with high cytolytic activity in an ADCC assay without additional
MDX-H210.
In vivo, erythema of involved skin areas in three patients and
pain at tumour sites after antibody infusion suggest the induction
of an inflammatory response within tumour lesions. In addition,
biopsies from a metastatic skin lesion revealed infiltration with
monocytes and PMN. Despite the fact that we were able to achieve
adequate plasma concentrations for up to 4 days, it was unlikely
that optimal concentrations of MDX-H210 were achieved within
the tumour, since unfortunately we could not detect MDX-H210 in
histological sections (data not shown), and failed to demonstrate
tumour imaging using technetium-labelled MDX-H210. In con-
trast, good imaging of the FcgRI-positive effector cell pool was
seen. One way of overcoming this limitation, probably caused by
the preferential binding of MDX-H210 to effector cells, could be to
either start Filgrastim after the administration of MDX-H210 to
reduce the accessible FcgRI-binding sites, or by altering the
pharmacokinetic properties of MDX-H210 to achieve high blood
levels over a longer period of time. One way could be repetitive
doses of MDX-H210, which might be limited by rapid HABA
induction seen in more than half of the patients in this study. A
BsAb construct with two fully humanised parts could help to
overcome this problem. Compared to complete IgG antibodies,
MDX-H210 has a very short half-life that cannot be fully explained
by the reduced size of about 100kDa. Since MDX-H210 lacks
binding sites for the neonatal Fc receptor FcRn, which is critical
for the serum half-life of IgG, engineered BsAb with altered
affinities for FcRn might also help to increase the serum half-life
(Ghetie and Ward, 2000). Another possibility of improving the off
rate of the antibody from tumour sites is to design BsAb with an
increased affinity for the tumour target, although a very high
affinity could lead to impaired tumour penetration (Adams et al,
2001).
The intention of this trial with BsAb MDX-H210 was to
utilise PMN as additional effector cells for breast cancer
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Figure 10 Plasma levels of soluble HER-2/neu. Soluble HER-2/neu levels
were measured during treatment with MDX-H210 and Filgrastim. A
significant decrease of sHer-2/neu was seen between 4h after the start of
infusion and 7 days (Po0.05). Data are presented as mean7s.e.m. of all
patients.
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limmunotherapy. This large cell population can be expanded and
activated by G-CSF, which also induced FcgRI expression.
Fortunately, concomitant treatment with MDX-H210 and Filgras-
tim did not lead to limiting toxicity. Although no objective
response could be documented in these heavily pretreated
patients with progressive breast cancer, biological effects were
noted. Thus, MDX-H210 can be safely administered in combina-
tion with Filgrastim, and leads to highly efficient, expanded
effector cell populations that may well have a significant
therapeutic impact when employed in an optimised extended
treatment schedule.
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